Last reviewed · How we verify

Cisplatin, Ifosfamide, Gemcitabine — Competitive Intelligence Brief

Cisplatin, Ifosfamide, Gemcitabine (Cisplatin, Ifosfamide, Gemcitabine) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination chemotherapy (platinum agent + alkylating agent + nucleoside analog). Area: Oncology.

phase 3 Combination chemotherapy (platinum agent + alkylating agent + nucleoside analog) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Cisplatin, Ifosfamide, Gemcitabine (Cisplatin, Ifosfamide, Gemcitabine) — European Lung Cancer Working Party. This is a combination chemotherapy regimen that uses three cytotoxic agents to damage cancer cell DNA and inhibit cell division.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Cisplatin, Ifosfamide, Gemcitabine TARGET Cisplatin, Ifosfamide, Gemcitabine European Lung Cancer Working Party phase 3 Combination chemotherapy (platinum agent + alkylating agent + nucleoside analog)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination chemotherapy (platinum agent + alkylating agent + nucleoside analog) class)

  1. European Lung Cancer Working Party · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Cisplatin, Ifosfamide, Gemcitabine — Competitive Intelligence Brief. https://druglandscape.com/ci/cisplatin-ifosfamide-gemcitabine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: